Marc Tessier-Lavigne
speaker
407 appearances
1 recordings
1 series
first heard Mar 2026
last heard 12 Mar
Marc Tessier-Lavigne’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Mar 2026 with 1.
Appearances
Many small companies are developing the technology and then seeking to partner or license that technology.
We're developing the technology.
We will do that as well.
But we're also making our own therapeutics.
And as I mentioned,
We're focused on large molecule therapeutics that are currently undruggable or hard to drug by conventional methods.
We have not described our therapeutic areas of interest or our timelines.
So since we haven't done that, I'm not going to do that here today, Sam.
But what I can tell you is this first, that we are focused on those hard to drug targets, the high hanging fruit.
As a biotech company, it's important to differentiate.
If you work on targets that are of high value but that are straightforward to drug by conventional means, there'll be a dozen companies working on those targets and it's hard to differentiate.
So we're going after the hard targets where people have not been successful at making drugs.
And that's what's driving our choice of targets in therapeutic areas currently, targets with some or a lot of validation that have been hard to drug by conventional means.
And so we are in multiple therapeutic areas currently, and we are pushing very hard to get to a clinic as rapidly as possible.
But that's all I'm willing to say about timelines at this point.
Well, thank you for this opportunity.
For me, what I'm passionate about is applying science to develop medicines that can help patients who are in need.
And I've been very fortunate to be able to work with some of the best companies.
I was chief scientific officer at Genentech.
I was on the board of Regeneron for a
Showing 361–380 of 407 · page 19 of 21
← Previous
Next →